Measurement of activated clotting time in children - Comparison of the Celite i-STAT® ACT with the Medtronic ACT® II

Acta Anaesthesiologica Scandinavica

Volumn 48, Issue 2, 2004, Pages 211-217

  Hug, Maja Isabel ^a   Di Bernardo, S ^a   Berger, F ^a   Bauersfeld, U ^a   Weiss, M ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

ACT; Activated clotting time; Coagulation testing; Heparin; Heparinization; Point of care testing

Indexed keywords

HEMOGLOBIN; HEPARIN;

ADOLESCENT; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; FEMALE; HEART CATHETERIZATION; HEPARINIZATION; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; TECHNIQUE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; PROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 0842305802     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2004.00296.x     Document Type: Article

References (17)

1. Bowers J, Ferguson JJ 3rd. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994; 17: 357-61.
2. Grady RM, Eisenberg PR, Bridges ND. Rational approach to use of heparin during cardiac catheterization in children. J Am Coll Cardiol 1995; 25: 725-9.
3. Siskin GP, Reiner E, Stainken BF et al. Activated clotting time as a screening test prior to catheter-based cardiovascular procedures. Catheter Cardiovasc Interv 2001; 54: 191-5.
4. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-40.
5. Seay RE, Uden DL, Kriesmer PJ, Payne NR. Predictive performance of three methods of activated clotting time measurement in neonatal ECMO patients. ASAIO J 1993; 39: 39-42.
6. Lin JC, Strauss RG, Kulhavy JC et al. Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics 2000; 106: E19.
7. Schneuwly OD, Reber G, Licker M, de Moerloose P. Celite ACT Measurement: Comparison of i-STAT®, a new assay system, with conventional Hemochron®. Thromb Haemost Suppl 2001, P679.
8. Sediame S, Zerah-Lancner F, d'Ortho MP, Adnot S, Harf A. Accuracy of the i-STAT® bedside blood gas analyser. Eur Respir J 1999; 14: 214-7.
9. Murthy JN, Hicks JM, Soldin SJ. Evaluation of i-STAT portable clinical analyzer in a neonatal and pediatric intensive care unit. Clin Biochem 1997; 30: 385-9.
10. Gault MH, Harding CE. Evaluation of i-STAT portable clinical analyzer in a hemodialysis unit. Clin Biochem 1996; 29: 117-24.
11. Papadea C, Foster J, Grant S et al. Evaluation of the i-STAT portable clinical analyzer for point-of care blood testing in the intensive care units of a university children's hospital. Ann Clin Lab Sci 2002; 32: 231-43.
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
13. Jahn UR, Van Aken H. Near-patient testing - point of care or point of costs and convenience? Br J Anaesth 2003; 90: 425-7.
14. Koster A, Despotis G, Gruendel M et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg 2002; 95: 26-30.
15. Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23: 907-10.
16. Weigthman WM, Clapin AO, Michalopoulis N, Gibbs NM. Sensitivity and specificity of the Hemochron, Hemotec and APTT for the detection of low concentrations of heparin. Anaesth Intensive Care 1996; 24: 472-6.
17. Ferguson JJ. All ACTs are not created equal. Tex Heart Inst J 1992; 19:1-3.